Abhijit Jagdale1, Huy Nguyen1, Hayato Iwase1, Jeremy B Foote2, Takayuki Yamamoto1, Mariyam Javed1, David Ayares3, Douglas J Anderson1, Devin E Eckhoff4, David K C Cooper1, Hidetaka Hara5. 1. Department of Surgery, University of Alabama at Birmingham, AL, USA. 2. Department of Microbiology and Animal Resources Program, University of Alabama at Birmingham, Birmingham, AL, USA. 3. Revivicor, Blacksburg, VA, USA. 4. Department of Surgery, University of Alabama at Birmingham, AL, USA; Department of Microbiology and Animal Resources Program, University of Alabama at Birmingham, Birmingham, AL, USA. 5. Department of Surgery, University of Alabama at Birmingham, AL, USA. Electronic address: harahjp@icloud.com.
Abstract
BACKGROUND: The aim was to monitor recovery of T/B lymphocytes in baboons after depletion by anti-thymocyte globulin (ATG) and anti-CD20mAb (Rituximab), followed by pig kidney transplantation and maintenance therapy with an anti-CD40mAb-based regimen. METHODS: In baboons (n = 14), induction was with ATG and anti-CD20mAb, and maintenance with (i) anti-CD40mAb, (ii) rapamycin, and (iii) methylprednisolone. Follow-up was for 6 months, or until rejection or other complication developed. Baboon blood was collected at intervals to measure T/B cells and subsets by flow cytometry. In a separate study in baboons receiving the same immunosuppressive regimen (n = 10), the populations of T/B lymphocytes in PBMCs, lymph nodes, and spleen were examined. RESULTS: After induction therapy, the total lymphocyte count and the absolute numbers of CD3+, CD4+, and CD8+T cells fell by >80%, and no CD22+B cells remained (all p < 0.001). T cell numbers began to recover early, but no CD22+B cells were present in the blood for 2 months. Recovery of both T and B cells remained at <30% of baseline (p < 0.001), even if rejection developed. At 6 months, effector memory CD8+T cells had increased more than other T cell subsets, but a greater percentage of B cells were naïve. In contrast to blood and spleen, T and B cells were not depleted in lymph nodes. CONCLUSIONS: ATG and anti-CD20mAb effectively decreased T and B lymphocytes in the blood and, in the presence of anti-CD40mAb maintenance therapy, recovery of these cells was inhibited. The recovery of effector memory CD8+T cells may be detrimental to long-term graft survival.
BACKGROUND: The aim was to monitor recovery of T/B lymphocytes in baboons after depletion by anti-thymocyte globulin (ATG) and anti-CD20mAb (Rituximab), followed by pig kidney transplantation and maintenance therapy with an anti-CD40mAb-based regimen. METHODS: In baboons (n = 14), induction was with ATG and anti-CD20mAb, and maintenance with (i) anti-CD40mAb, (ii) rapamycin, and (iii) methylprednisolone. Follow-up was for 6 months, or until rejection or other complication developed. Baboon blood was collected at intervals to measure T/B cells and subsets by flow cytometry. In a separate study in baboons receiving the same immunosuppressive regimen (n = 10), the populations of T/B lymphocytes in PBMCs, lymph nodes, and spleen were examined. RESULTS: After induction therapy, the total lymphocyte count and the absolute numbers of CD3+, CD4+, and CD8+T cells fell by >80%, and no CD22+B cells remained (all p < 0.001). T cell numbers began to recover early, but no CD22+B cells were present in the blood for 2 months. Recovery of both T and B cells remained at <30% of baseline (p < 0.001), even if rejection developed. At 6 months, effector memory CD8+T cells had increased more than other T cell subsets, but a greater percentage of B cells were naïve. In contrast to blood and spleen, T and B cells were not depleted in lymph nodes. CONCLUSIONS: ATG and anti-CD20mAb effectively decreased T and B lymphocytes in the blood and, in the presence of anti-CD40mAb maintenance therapy, recovery of these cells was inhibited. The recovery of effector memory CD8+T cells may be detrimental to long-term graft survival.
Authors: D C Brennan; K Flavin; J A Lowell; T K Howard; S Shenoy; S Burgess; S Dolan; J M Kano; M Mahon; M A Schnitzler; R Woodward; W Irish; G G Singer Journal: Transplantation Date: 1999-04-15 Impact factor: 4.939
Authors: M M Mohiuddin; P C Corcoran; A K Singh; A Azimzadeh; R F Hoyt; M L Thomas; M A Eckhaus; C Seavey; D Ayares; R N Pierson; K A Horvath Journal: Am J Transplant Date: 2011-11-09 Impact factor: 8.086
Authors: Takayuki Yamamoto; Qi Li; Hidetaka Hara; Liaoran Wang; Hongmin Zhou; Juan Li; Devin E Eckhoff; A Joseph Tector; Edwin C Klein; Ray Lovingood; Mohamed Ezzelarab; David Ayares; Yi Wang; David K C Cooper; Hayato Iwase Journal: Transpl Immunol Date: 2018-08-06 Impact factor: 1.708
Authors: E J Kim; J Kwun; A C Gibby; J J Hong; A B Farris; N N Iwakoshi; F Villinger; A D Kirk; S J Knechtle Journal: Am J Transplant Date: 2014-01 Impact factor: 8.086
Authors: L Bühler; M Awwad; M Basker; S Gojo; A Watts; S Treter; K Nash; G Oravec; Q Chang; A Thall; J D Down; M Sykes; D Andrews; R Sackstein; M E White-Scharf; D H Sachs; D K Cooper Journal: Transplantation Date: 2000-06-15 Impact factor: 4.939
Authors: Hayato Iwase; Hidetaka Hara; Mohamed Ezzelarab; Tao Li; Zhongqiang Zhang; Bingsi Gao; Hong Liu; Cassandra Long; Yi Wang; Amy Cassano; Edwin Klein; Carol Phelps; David Ayares; Abhinav Humar; Martin Wijkstrom; David K C Cooper Journal: Xenotransplantation Date: 2017-03-17 Impact factor: 3.907
Authors: Huidong Zhou; Hayato Iwase; Roman F Wolf; Burcin Ekser; Mohamed Ezzelarab; Hidetaka Hara; Gary White; David K C Cooper Journal: Xenotransplantation Date: 2014-02-18 Impact factor: 3.907
Authors: Muhammad M Mohiuddin; Avneesh K Singh; Philip C Corcoran; Robert F Hoyt; Marvin L Thomas; Billeta G T Lewis; Michael Eckhaus; Nicole L Dabkowski; Aaron J Belli; Keith A Reimann; David Ayares; Keith A Horvath Journal: Xenotransplantation Date: 2013-10-29 Impact factor: 3.907